Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Crescita Therpeutc ( (TSE:CTX) ) just unveiled an update.
Crescita Therapeutics reported its financial results for Q4 and fiscal year 2024, highlighting a revenue increase but a net loss due to higher operating expenses. Despite financial challenges, the company made strategic moves such as acquiring Aquafolia, securing a U.S. distribution agreement for Pliaglis, and amending a supply agreement with a major client, which are expected to enhance future profitability and market presence.
More about Crescita Therpeutc
Crescita Therapeutics Inc. is a Canadian commercial dermatology company focused on growth and innovation. It operates in the dermatology industry, offering a range of dermatological products and services. The company is known for its strategic market focus, including the acquisition of Aquafolia and partnerships in manufacturing and medical aesthetics.
YTD Price Performance: -11.86%
Average Trading Volume: 16,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$10.48M
For detailed information about CTX stock, go to TipRanks’ Stock Analysis page.